Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 87

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Tetraiodothyroacetic acid, a small molecule integrin ligand, blocks angiogenesis induced by vascular endothelial growth factor and basic fibroblast growth factor

Mousa, Shaker A., Bergh, Joel J., Dier, Emie, Rebbaa, Abdelhadi, O’Connor, Laura J., Yalcin, Murat, Aljada, Ahmad, Dyskin, Evgeny, Davis, Faith B., Lin, Hung-Yung, Davis, Paul J. · 2008 · Angiogenesis

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s10456-007-9088-7

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Research works printed but not linked: 34

  1. Davis FB, Mousa SA, O′Connor L et al (2004) Proangiogenic action of thyroid hormone is fibroblast growth factor-dependent and is initiated at the cell surface. Circ Res 94:1500–1556 · DOI · Paper page
  2. Mousa SA, O′Connor L, Davis FB et al (2006) Proangiogenesis action of the thyroid hormone analog 3,5-diiodothyropropionic acid (DITPA) is initiated at the cell surface and is integrin mediated. Endocrinology 147:1602–1607 · DOI
  3. Mousa SA, O′Connor LJ, Bergh JJ et al (2005) The proangiogenic action of thyroid hormone analogue GC-1 is initiated at an integrin. J Cardiovasc Pharmacol 46:356–360 · DOI · Paper page
  4. Mousa SA, Mohamed S, Davis PJ et al (2006) Pro-angiogenesis action of thyroid hormone and analogs in a three-dimensional in vitro microvascular endothelial sprouting model. Int Angiol 25:407–413
  5. Bergh JJ, Lin HY, Lansing L et al (2005) Integrin alphaVbeta3 contains a cell surface receptor site for thyroid hormone that is linked to activation of mitogen-activated protein kinase and induction of angiogenesis. Endocrinology 146:2864–2871 · DOI · Paper page
  6. Wu SY, Green WL, Huang WS et al (2005) Alternate pathways of thyroid hormone metabolism. Thyroid 15:943–958 · DOI · Paper page
  7. Davis PJ, Shih A, Lin HY et al (2000) Thyroxine promotes association of mitogen-activated protein kinase and nuclear thyroid hormone receptor (TR) and causes serine phosphorylation of TR. J Biol Chem 275:38032–38039 · DOI · Paper page
  8. Tang HY, Lin HY, Zhang S et al (2004) Thyroid hormone causes mitogen-activated protein kinase-dependent phosphorylation of the nuclear estrogen receptor. Endocrinology 145:3265–3272 · DOI · Paper page
  9. Davis FB, Tang HY, Shih A, Keating T et al (2006) Acting via a cell surface receptor, thyroid hormone is a growth factor for glioma cells. Cancer Res 66:7270–7275 · DOI · Paper page
  10. Plow EF, Haas TA, Zhang L et al (2000) Ligand binding to integrins. J Biol Chem 275:21785–21788 · DOI · Paper page
  11. Giannone G, Dubin-Thaler BJ, Dobereiner HG et al (2004) Periodic lamellipodial contractions correlate with rearward actin waves. Cell 116:431–443 · DOI · Paper page
  12. Ridley AJ (2004) Pulling back to move forward. Cell 116:357–358 · DOI
  13. Arnaout MA, Mahalingam B, Xiong JP (2005) Integrin structure, allostery, and bidirectional signaling. Annu Rev Cell Dev Biol 21:381–410 · DOI · Paper page
  14. Mahabeleshwar GH, Feng W, Phillips DR et al (2006) Integrin signaling is critical for pathological angiogenesis. J Exp Med 203:2495–2507 · DOI · Paper page
  15. Soldi R, Mitola S, Strasly M et al (1999) Role of αVβ3 integrin in the activation of vascular endothelial growth factor receptor-2. EMBO J 18:882–892 · DOI · Paper page
  16. Masson-Gadais B, Houle F, Laferriere J et al (2003) Integrin αVβ3, requirement for VEGFR2-mediated activation of SAPK2/p38 and Hsp90-dependent phosphorylation of focal adhesion kinase in endothelial cells activated by VEGF. Cell Stress Chaperones 8:37–52 · doi:10.1379/1466-1268(2003)8
  17. Rawlings NG, Simko E, Bebchuk T et al (2003) Localization of integrin αVβ3 and vascular endothelial growth factor receptor-2 (KDR/Flk-1) in cutaneous and oral melanomas of dog. Histol Histopathol 18:819–826
  18. Davis PJ, Davis FB, Cody V (2005) Membrane receptors mediating thyroid hormone action. Trends Endocrinol Metab 16:429–435 · DOI · Paper page
  19. Cody V, Davis PJ, Davis FB (2007) Molecular modeling of the thyroid hormone interactions with alphavbeta3 integrin. Steroids 72:165–170 · DOI
  20. Ausprunk DH, Knighton DR, Folkman J (1975) Vascularization of normal and neoplastic tissues grafted to the chick chorioallantoic. Role of host and preexisting graft blood vessels. Am J Pathol 79:597–628
  21. Nehls V, Drenckhahn D (1995) A microcarrier-based cocultivation system for the investigation of factors and cells involved in angiogenesis in three-dimensional fibrin matrices in vitro. Histochem Cell Biol 104:459–466 · DOI
  22. Nehls V, Drenckhahn D (1995) A novel, microcarrier-based in vitro assay for rapid and reliable quantification of three-dimensional cell migration and angiogenesis. Microvasc Res 50:311–322 · DOI · Paper page
  23. Powell JA, Mohamed SN, Kerr JS et al (2000) Antiangiogenesis efficacy of nitric oxide donors. J Cell Biochem 80(1):104–114 · DOI
  24. Kerbel RS (2006) Antiangiogenic therapy: a universal chemosensitization strategy for cancer? Science 312:1171–1175 · DOI · Paper page
  25. Persano L, Crescenzi M, Indraccolo S (2007) Anti-angiogenic gene therapy of cancer: current status and future prospects. Mol Aspects Med 28:87–114 · DOI
  26. Folkman J (2006) Antiangiogenesis in cancer therapy—endostatin and its mechanisms of action. Exp Cell Res 312:594–607 · DOI · Paper page
  27. Vredenburgh JJ, Desjardins A, Herndon JE et al (2007) Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 13:1253–1259 · DOI · Paper page
  28. Motzer RJ, Hutson TE, Tomczak P et al (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115–124 · DOI · Paper page
  29. Escudier B, Eisen T, Stadler WM et al (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125–134 · DOI · Paper page
  30. Tsutsui S, Inoue H, Yasuda K et al (2006) Angiopoietin 2 expression in invasive ductal carcinoma of the breast: its relationship to the VEGF expression and microvessel density. Breast Cancer Res Treat 98:261–266 · DOI
  31. Yoshiji H, Kuriyama S, Noguchi R et al (2005) Angiopoietin 2 displays a vascular endothelial growth factor dependent synergistic effect in hepatocellular carcinoma development in mice. Gut 54:1768–1775 · DOI
  32. Mandriota SJ, Pepper MS (1998) Regulation of angiopoietin-2 mRNA levels in bovine microvascular endothelial cells by cytokines and hypoxia. Circ Res 83:852–859 · DOI · Paper page
  33. Pittman CS, Shimizu T, Burger A et al (1980) The non de-iodinative pathways of thyroxine metabolism: 3,5,3′,5-tetraiodothyroacetic acid turnover in normal and fasting human subjects. J Clin Endocrinol Metab 50:712–716 · DOI
  34. Lin HY, Tang HY, Shih A et al (2007) Thyroid hormone is a MAPK-dependent growth factor for thyroid cancer cells and is anti-apoptotic. Steroids 72:180–187 · DOI

Cited by

See all 87

Metadata

Authors
Mousa, S. A., Bergh, J. J., Dier, E., Rebbaa, A., O’Connor, L. J., Yalcin, M., Aljada, A., Dyskin, E., Davis, F. B., Lin, H.-Y., & Davis, P. J.
Venue
Angiogenesis
Published
2007-12-13
Volume
11
Issue
2
Pages
183-190
ISSN
  • 0969-6970
  • 1573-7209
Cited by
87
References
1
Language
en
Licence
www.springer.com/tdm (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Tetraiodothyroacetic acid, a small molecule integrin ligand, blocks angiogenesis induced by vascular endothelial growth factor and basic fibroblast growth factor. https://app.cochat.ai/papers/10.1007/s10456-007-9088-7
The paper
Mousa, S. A., Bergh, J. J., Dier, E., Rebbaa, A., O’Connor, L. J., Yalcin, M., Aljada, A., Dyskin, E., Davis, F. B., Lin, H.-Y., & Davis, P. J. (2008). Tetraiodothyroacetic acid, a small molecule integrin ligand, blocks angiogenesis induced by vascular endothelial growth factor and basic fibroblast growth factor. Angiogenesis. https://doi.org/10.1007/s10456-007-9088-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.